A group of investors led a $125m funding round in Nimbus Therapeutics.

A group of investors, including Bain Capital, SV Health Investors, Access Biotechnology, Atlas Venture, BVF Partners, Bill Gates, Lightstone Ventures, Pfizer Ventures, RA Capital Management and SR One, led a $125m funding round in Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine. "The strong support from investors in this financing validates the promise and differentiation of Nimbus’ current portfolio of clinical and preclinical programs, and the success of our productive drug discovery engine. I’m pleased to welcome SV Health Investors and Bain Capital Life Sciences to Nimbus’ investor syndicate at this very exciting time in our history, and look forward to generating and sharing critical data for our medicines in development in the near term," Jeb Keiper, Nimbus CEO.